Aleksandra Adamska

TL;DR: Currently available therapies and clinical trials are summarized, directed towards a plethora of pathways and components dysregulated during PDAC carcinogenesis, and emerging trends towards targeted therapies as the most promising approach are discussed.

TL;DR: The cellular and molecular effects of current chemotherapy drugs such as gemcitabine, FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and ABRAXANE and various microenvironmental factors capable of instigating PDAC to develop resistance to chemotherapeutic drugs are described.

TL;DR: A more targeted approach of ABC transporters should be implemented that considers which specific transporter is playing a major role in a particular tumour setting in order to achieve a more successful outcome for ABCtransporters inhibitors in cancer therapy.

TL;DR: The results demonstrate the important role played by GPR55 downstream of p53 in PDAC progression and indicate that combination of CBD and GEM might be tested in clinical trials as a novel promising treatment to improve PDAC patients’ outcome.

TL;DR: The role of ABC transporters in the development and progression of malignancies, with focus on PDAC, is explored, and an emerging role for ABCtransporters as prognostic tools for patients’ survival will be discussed, demonstrating the therapeutic potential of ABCTransport in cancer therapy.